Mitchell E. Gross, MD, PhD

Associate Professor of Clinical Medicine

Image of Mitchell E. Gross, MD, PhD
Is this your profile? Click to edit

Overview

Dr. Gross is research director of the USC Norris Westside Cancer Center and the Center for Applied Molecular Medicine. His overall research interest focuses on applying modern techniques relating to the study of genes and proteins (genomics and proteomics) on the clinical problems faced in treating patients with prostate cancer. A particular interest relates to the androgen receptor and relating proteins and pathways as key driving forces behind the development and treatment of prostate cancer. As a medical oncologist, his clinical activities are focused on therapeutic clinical trials incorporating both molecularly targeted and conventional therapies to the care of patients with prostate cancer. He serves as primary investigator on many multi-center phase 1 and 2 clinical trials

Dr. Gross has earned degrees from the University of California, San Diego (B.A.), Baylor College of Medicine in Houston (M.D.), and the University of California, Los Angeles (Ph.D. Molecular Biology). He completed a residency in internal medicine and a fellowship in hematology and medical oncology at the UCLA Center for the Health Sciences.

Awards

  • Phi Beta Kappa, 1989
  • UCSD/Revelle College Academic: Leadership Award, 1990
  • Alpha Omega Alpha, 1994
  • Hewlett Packard Award for Excellence in Internal Medicine, 1994
  • Specialty Training Advanced Research Fellowship, 1997
     – 2002
  • Amgen Fellowship Research Award, 1999
  • Rhone Phoulenc Rorer Travel Award, 1999
  • AACR-AFLAC Scholar in Training Award,, 2001
  • Donna and Jesse Garber Award, 2006

Research Funding

  • Selective Cancer Treatment Based on High Frequency Ultrasonic Beam
    NIH · R21EB022932 · Sep 16, 2016 – Jul 31, 2018 · Role: Co-Principal Investigator
  • Role of PIASy in Androgen Signaling and Prostate Cancer
    NIH · K08DK064379 · Aug 21, 2002 – Jun 30, 2007 · Role: Principal Investigator

Publications

  • Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 08; 17(4):241-247.e1.. View in PubMed
  • Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells. Prostate. 2019 05; 79(6):667-677.. View in PubMed
  • Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis. Oncogene. 2019 04; 38(16):3003-3018.. View in PubMed
  • Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2). Oncotarget. 2018 Jun 08; 9(44):27363-27379.. View in PubMed
  • Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate. Oncogene. 2018 09; 37(38):5175-5190.. View in PubMed
  • Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. BMC Cancer. 2018 04 03; 18(1):368.. View in PubMed
  • Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles. ACS Biomater Sci Eng. 2017 Dec 11; 3(12):3273-3282.. View in PubMed
  • Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clin Genitourin Cancer. 2017 Jul 14.. View in PubMed
  • A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy. BMJ Open. 2017 Jul 10; 7(7):e016910.. View in PubMed
  • Automated analysis of co-localized protein expression in histologic sections of prostate cancer. PLoS One. 2017; 12(5):e0178362.. View in PubMed